Supernus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company has launched Oxtellar XR and Trokendi XR, its two treatments for epilepsy. In addition, the company has launched Trokendi XR for the prophylaxis of migraine headache in adults and adolescents. The company's product candidates for the treatment of psychiatric disorders include: SPN-810 to treat impulsive aggression in children and adolescents who have attention deficit hyperactivity disorder (ADHD); SPN-812, a non-stimulant candidate to treat patients who have ADHD; SPN-809 for the treatment of depression; and SPN-604 for the treatment of bipolar.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.